<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886246</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0025</org_study_id>
    <secondary_id>2018-003080-56</secondary_id>
    <nct_id>NCT03886246</nct_id>
  </id_info>
  <brief_title>A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130</brief_title>
  <official_title>An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and efficacy of BI 655130 in patients with GPP, who have&#xD;
      completed previous BI 655130 trials and are qualified for entry in this trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">January 20, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment emergent adverse events (TEAEs) up to week 252 of maintenance treatment</measure>
    <time_frame>Up to 252 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The reoccurrence of a GPP flare defined by GPPGA</measure>
    <time_frame>Up to 252 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first achievement of a GPPGA score of 0 or 1 (Patients received flare rescue Treatment)</measure>
    <time_frame>Up to 252 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A GPPGA pustulation sub-score of 0 indicating no visible pustules, by visit</measure>
    <time_frame>Up to 252 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Psoriasis Symptom Scale (PSS) score, by visit</measure>
    <time_frame>Up to 252 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Generalized Pustular Psoriasis</condition>
  <arm_group>
    <arm_group_label>Spesolimab (every 6 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spesolimab (every 12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spesolimab (every 4 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spesolimab</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Spesolimab (every 6 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spesolimab</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Spesolimab (every 12 weeks)</arm_group_label>
    <arm_group_label>Spesolimab (every 4 weeks)</arm_group_label>
    <arm_group_label>Spesolimab (every 6 weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients who have completed the treatment period without premature&#xD;
             discontinuation in the previous BI 655130 trial and are willing and able to continue&#xD;
             treatment in the current trial&#xD;
&#xD;
          -  Women of childbearing potential must be ready and able to use highly effective methods&#xD;
             of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per&#xD;
             year when used consistently and correctly. A list of contraception methods meeting&#xD;
             these criteria is provided in Section 4.2.2.3 as well as in the patient information.&#xD;
             Note: A woman is considered of childbearing potential, i.e. fertile, following&#xD;
             menarche and until becoming postmenopausal unless permanently sterile. Permanent&#xD;
             sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral&#xD;
             oophorectomy. Tubal ligation is not a method of permanent sterilization. A&#xD;
             postmenopausal state is defined as no menses for 12 months without an alternative&#xD;
             medical cause.&#xD;
&#xD;
          -  Signed and dated written informed consent and assent for the current trial 1368-0025,&#xD;
             in accordance with ICH-GCP and local legislation prior to admission to the current&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any restricted medication, or any drugs considered by the investigator&#xD;
             likely to interfere with the safe conduct of the study since the last visit of the&#xD;
             previous BI 655130 trial and during the screening period for the current trial&#xD;
&#xD;
          -  Severe, progressive, or uncontrolled hepatic disease, defined as &gt;3- fold Upper Limit&#xD;
             of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or &gt;2- fold ULN&#xD;
             elevation in total bilirubin.&#xD;
&#xD;
          -  Patients with congestive heart disease, as assessed by the investigator.&#xD;
&#xD;
          -  Relevant chronic or acute infections including human immunodeficiency virus (HIV) or&#xD;
             viral hepatitis. A patient can be re-screened if the patient was treated and is cured&#xD;
             from acute infection.&#xD;
&#xD;
          -  History of allergy/hypersensitivity to a systemically administered trial medication&#xD;
             agent or its excipients.&#xD;
&#xD;
          -  Any documented active or suspected malignancy at screening, except appropriately&#xD;
             treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in&#xD;
             situ carcinoma of uterine cervix.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.&#xD;
             Women who stop nursing before the study drug administration do not need to be excluded&#xD;
             from participating; they should refrain from breastfeeding up to 16 weeks after the&#xD;
             study drug administration&#xD;
&#xD;
          -  Major surgery (major according to the investigator's assessment) performed since the&#xD;
             last visit of previous BI 655130 trial or planned during the current trial, e.g. hip&#xD;
             replacement, aneurysm removal, stomach ligation), as assessed by the investigator.&#xD;
&#xD;
          -  Evidence of a current or previous disease, medical condition (including chronic&#xD;
             alcohol or drug abuse or any condition) other than GPP, surgical procedure,&#xD;
             psychiatric or social problems, medical examination finding (including vital signs and&#xD;
             electrocardiogram [ECG]), or laboratory value at the screening outside the reference&#xD;
             range that in the opinion of the investigator is clinically significant and would make&#xD;
             the study participant unreliable to adhere to the protocol, comply with all study&#xD;
             visits/procedures or to complete the trial, compromise the safety of the patient or&#xD;
             compromise the quality of the data.&#xD;
&#xD;
          -  Patients with a confirmed active infection with SARS-CoV-2 (as confirmed by PCR test).&#xD;
             A patient may be enrolled once recovered from SARS-CoV-2 infection according to the&#xD;
             investigator's assessment.&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oakland Hills Dermatology</name>
      <address>
        <city>Auburn Hills</city>
        <state>Michigan</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christofer Buatti</last_name>
      <phone>+001(248)858-2255</phone>
      <email>chrisbuatti@clinvax.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lebwohl</last_name>
      <phone>+001(212)844-3288</phone>
      <email>mark.lebwohl@mountsinai.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhua Xu</last_name>
      <phone>13818978539</phone>
      <email>xjhhsyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Beylot-Barry</last_name>
      <phone>+33(0)557822500</phone>
      <email>marie.beylot-barry@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Bachelez</last_name>
      <phone>+33(0)142499817</phone>
      <email>herve.bachelez@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuelle-Anne Viguier</last_name>
      <phone>+33(0)326784343</phone>
      <email>mviguier@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamran Ghoreschi</last_name>
      <phone>+49(30)450518062</phone>
      <email>kamran.ghoreschi@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn AöR</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Wilsmann-Theis</last_name>
      <phone>+49(228)28715370</phone>
      <email>Dagmar.Wilsmann-Theis@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Campus</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Rueff</last_name>
      <phone>+49(89)440056661</phone>
      <email>Franziska.Rueff@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akimichi Morita</last_name>
      <phone>+81528515511</phone>
      <email>amorita@med.nagoya-cu.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Gyun Kim</last_name>
      <phone>82-2-2228-1837</phone>
      <email>tgmed83@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>George Town</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wooi Chiang Tan</last_name>
      <phone>6042225250</phone>
      <email>tanwooichiang@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azura Binti Mohd Affandi</last_name>
      <phone>60326155555(1540)</phone>
      <email>affandi_azura@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pakar Sultanah Fatimah</name>
      <address>
        <city>Muar</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Medical Center Azbuka Zdorovia&quot;</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bulat Khalilov</last_name>
      <phone>+78435280206</phone>
      <email>bvh099@rambler.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Lixian Tan</last_name>
      <phone>67795555</phone>
      <email>chris_lixian_tan@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natta Rajatanavin</last_name>
      <phone>+6622011211</phone>
      <email>natta.rama@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Farhat Hached Hospital</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Denguezli</last_name>
      <phone>0021673211183</phone>
      <email>denguezli1961@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hedi Chaker Hospital, Department of Dermatology</name>
      <address>
        <city>Tunisia</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamida Turki</last_name>
      <phone>+21674242627</phone>
      <email>hamida.turki@rns.tn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

